MigraineMind research summary

Plasma adrenomedullin and response to erenumab in migraine: a REFORM study.

Brain Commun | 2026

Observational study
AuthorsAl-Khazali HM, Karlsson WK, Christensen RH, Dominguez-Moreno R, Ashina M
JournalBrain Commun
Publication year2026
PubMed ID43060847

Summary

This research explored how plasma adrenomedullin levels relate to migraine treatment. Adrenomedullin is linked to migraine biology and resembles a key migraine-related peptide. Researchers wanted to know if measuring adrenomedullin could help predict who benefits from erenumab treatment. In the study, adults with episodic or chronic migraines received erenumab injections every four weeks for six months. They measured plasma adrenomedullin levels before treatment, after 24 weeks, and after 48 weeks. The main goal was to see if initial adrenomedullin levels correlated with a significant reduction in monthly migraine days. The study aimed to determine if this biomarker could identify patients who would respond well to erenumab. Understanding this relationship could lead to better treatment strategies for migraine patients in the future, particularly for those who might not respond to standard therapies. Clinical relevance: This research indicates that measuring plasma adrenomedullin could help identify migraine patients likely to benefit from erenumab treatment.

Related migraine research topics

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.